Cenicriviroc
- Generic Name
- Cenicriviroc
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C41H52N4O4S
- CAS Number
- 497223-25-3
- Unique Ingredient Identifier
- 15C116UA4Y
- Background
Cenicriviroc has been used in trials studying the treatment of HIV-infection/AIDS, AIDS Dementia Complex, Nonalcoholic Steatohepatitis, Human Immunodeficiency Virus, and HIV-1-Associated Cognitive Motor Complex.
- Associated Conditions
- -
- Associated Therapies
- -
I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients
- Conditions
- Interventions
- First Posted Date
- 2020-07-27
- Last Posted Date
- 2024-03-19
- Lead Sponsor
- QuantumLeap Healthcare Collaborative
- Target Recruit Count
- 1500
- Registration Number
- NCT04488081
- Locations
- ๐บ๐ธ
Columbia University Medical Center, New York, New York, United States
๐บ๐ธSanford Health, Sioux Falls, South Dakota, United States
๐บ๐ธUniversity of Rochester Medical Center, Rochester, New York, United States
Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites
- First Posted Date
- 2017-12-19
- Last Posted Date
- 2018-01-11
- Lead Sponsor
- Allergan
- Target Recruit Count
- 16
- Registration Number
- NCT03376841
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธClinical Pharmacology of Miami, Miami, Florida, United States
Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Participants With Nonalcoholic Steatohepatitis
- Conditions
- Interventions
- First Posted Date
- 2017-02-23
- Last Posted Date
- 2022-02-02
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 167
- Registration Number
- NCT03059446
- Locations
- ๐ฉ๐ช
Universitaetsklinikum Heidelberg - Innere Medizin IV, Heidelberg, Germany
๐ฉ๐ชUniklinik Koeln, Poliklinik fuer Endokrinologie, Diabetologie und Praeventivmedizin (ZEDP), Koeln, Germany
๐ฌ๐งQueen Alexandra Hospital, Portsmouth, United Kingdom
AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)
- First Posted Date
- 2017-01-23
- Last Posted Date
- 2022-03-10
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 1778
- Registration Number
- NCT03028740
- Locations
- ๐บ๐ธ
Gastroenterology Associates of Fairfield County, Bridgeport, Connecticut, United States
๐บ๐ธQway Research, LLC, Hialeah, Florida, United States
๐บ๐ธOptions Health Research, Tulsa, Oklahoma, United States
Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination
- First Posted Date
- 2016-02-18
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT02684799
- Locations
- ๐บ๐ธ
SeaView Research, Inc., Miami, Florida, United States
Pharmacokinetic and Safety Study of Cenicriviroc and Pioglitazone, When Dosed Alone or in Combination
- First Posted Date
- 2015-01-19
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT02342067
- Locations
- ๐บ๐ธ
DaVita Clinical Research, Lakewood, Colorado, United States
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 289
- Registration Number
- NCT02217475
Effect of Cenicriviroc on HIV Neurocognitive Impairment
- Conditions
- Interventions
- First Posted Date
- 2014-05-01
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- University of Hawaii
- Target Recruit Count
- 20
- Registration Number
- NCT02128828
- Locations
- ๐บ๐ธ
Clint Spencer Clinic, Honolulu, Hawaii, United States
Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam
- Conditions
- Interventions
- First Posted Date
- 2013-04-09
- Last Posted Date
- 2014-04-09
- Lead Sponsor
- Tobira Therapeutics, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT01827540
- Locations
- ๐บ๐ธ
SeaView Research, Inc., Miami, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.